- All sections
- A - Human necessities
- A61P - Specific therapeutic activity of chemical compounds or medicinal preparations
- A61P 5/44 - GlucocorticosteroidsDrugs increasing or potentiating the activity of glucocorticosteroids
Patent holdings for IPC class A61P 5/44
Total number of patents in this class: 127
10-year publication summary
|
0
|
3
|
2
|
3
|
3
|
7
|
4
|
12
|
6
|
3
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Corcept Therapeutics, Inc. | 349 |
6 |
| Ardelyx, Inc. | 115 |
5 |
| Chiesi Farmaceutici S.p.A. | 971 |
5 |
| Nicox S.A. | 138 |
5 |
| Gilead Sciences, Inc. | 2056 |
4 |
| Santen Pharmaceutical Co., Ltd. | 601 |
3 |
| Schering Corporation | 436 |
3 |
| Mallinckrodt ARD IP Limited | 7 |
3 |
| Glaxo Group Limited | 4122 |
2 |
| Merck & Co., Inc. | 306 |
2 |
| Boehringer Ingelheim International GmbH | 4640 |
2 |
| Boehringer Ingelheim Pharma GmbH & Co. Kg | 538 |
2 |
| Board of Regents, The University of Texas System | 5869 |
2 |
| Board of Regents of the University of Nebraska | 767 |
2 |
| Case Western Reserve University | 1841 |
2 |
| DuoCort Pharma AB | 2 |
2 |
| Eli Lilly and Company | 3902 |
2 |
| Generics [UK] Limited | 118 |
2 |
| MetrioPharm AG | 49 |
2 |
| Plus Chemicals SA | 20 |
2 |
| Other owners | 69 |